US · ENSC
Ensysce Biosciences, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- La Jolla, CA 92037
- Website
- ensysce.com
Price · as of 2024-12-31
$0.39
Market cap 1.48M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $16,029,569.61 | +4,120,711,882.01% |
| Intrinsic Value(DCF) | $2.01 | +416.71% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $34,380.00 | ||||
| 2018 | $35,856.00 | ||||
| 2019 | $37,260.00 | ||||
| 2020 | $50,832.00 | $20,683.32 | $1.04 | $0.00 | $1.60 |
| 2021 | $3,960.00 | $160,800.00 | $0.00 | $0.00 | $562.89 |
| 2022 | $101.70 | $278.85 | $0.00 | $0.00 | $2,582.86 |
| 2023 | $11.77 | $254.24 | $0.00 | $0.00 | $13.90 |
| 2024 | $5.02 | $16,029,569.61 | $17,473.30 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Ensysce Biosciences, Inc.'s (ENSC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $16,029,569.61
- Current price
- $0.39
- AI upside
- +4,120,711,882.01%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.01
+416.71% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ENSC | Ensysce Biosciences, Inc. | $0.39 | 1.48M | +4,120,711,882% | +417% | — | — | -1.10 | 2.36 | 1.68 | -0.83 | — | 2.36 | -38.57% | -129.17% | -153.30% | -471.83% | 16069.72% | -192.33% | 0.08 | -5.22 | 2.42 | 1.64 | 0.48 | -256.00% | 13353.00% | 6959834645.00% | -85550186.53% | -3399198.17 | 17914756446.99% | 3306.75% | -3630.90% | 3340.18% | -0.83 | 0.00 | 1.07 | -32.39 |
| KALA | KALA BIO, Inc. | $0.38 | 8.33M | — | — | — | — | -1.01 | 3.16 | — | -0.49 | — | 3.16 | 0.00% | — | — | -388.29% | 599.82% | -69.12% | 2.62 | -7.09 | 3.11 | 3.02 | 0.46 | -5977.00% | — | 369.00% | -76.03% | -1.73 | 433.08% | 0.00% | 0.00% | 11.20% | -0.49 | -0.68 | — | -17.97 |
| KZIA | Kazia Therapeutics Limite… | $8.45 | 13.69M | +90% | -63% | — | +12,468% | -0.63 | -1.56 | 309.03 | -0.68 | — | -1.38 | 100.00% | -33850.00% | -49290.48% | 226.03% | 112.59% | -149.76% | -0.05 | — | 0.35 | 0.32 | 0.30 | -6564.00% | -9818.00% | 3859.00% | -102.30% | -0.94 | 114.02% | 0.00% | 0.00% | 22.54% | -0.64 | -0.68 | 215.01 | -40.14 |
| QLGN | Qualigen Therapeutics, In… | $3.21 | 5.43M | +38,771% | — | — | — | -0.18 | 0.42 | — | 0.01 | -0.03 | 0.42 | 0.00% | — | — | -2210.05% | -3863.24% | -189.27% | 0.00 | -6.34 | 2.33 | 1.59 | 0.22 | 60244.00% | -10000.00% | -3859.00% | -560.87% | -3.15 | -4242.60% | 7.77% | -1.40% | 191.43% | 0.01 | 0.01 | — | -39.80 |
| SNGX | Soligenix, Inc. | $1.18 | 11.9M | — | — | — | — | -0.48 | 0.96 | — | 0.25 | — | 0.96 | 0.00% | — | — | -248.97% | 387.20% | -88.11% | 0.36 | — | 1.82 | 1.61 | 0.67 | -6066.00% | — | -233.00% | -213.60% | -1.73 | 361.77% | 0.00% | 0.00% | 35.16% | 0.25 | 0.29 | — | -38.99 |
| VYNE | VYNE Therapeutics Inc. | $0.60 | 10.01M | +3,912% | -43% | — | — | -0.98 | 0.93 | 45.39 | 0.12 | — | 0.93 | 0.00% | -4690.53% | -4646.14% | -66.33% | 505.69% | -54.57% | 0.00 | — | 12.53 | 12.11 | 0.90 | -3404.00% | 1377.00% | -283.00% | -128.02% | -13.83 | 626.52% | 0.00% | 0.00% | 16.23% | 0.12 | 0.09 | -5.50 | -30.50 |
| XBIO | Xenetic Biosciences, Inc. | $2.53 | 3.9M | +10,942% | -5% | — | — | -1.47 | 0.97 | 2.32 | 0.09 | — | 0.97 | 100.00% | -168.16% | -158.39% | -50.12% | -1285.35% | -45.24% | 0.00 | — | 7.37 | 6.89 | 1.52 | -517.00% | -156.00% | -3152.00% | -48.55% | -3.15 | -861.34% | 0.00% | 0.00% | 0.00% | 0.09 | 0.13 | -0.14 | -36.77 |
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
- CEO
- D. Lynn Kirkpatrick
- Employees
- 7
- Beta
- 1.15
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.01 ÷ $0.39) − 1 = +416.71% (DCF, example).